サマリー

がん遺伝子治療市場は、2020年に1,389.42百万ドルとなり、2030年には11,359.35百万ドルに達すると推定され、2021年から2030年までのCAGRは23.3%を記録している。がんは、体の他の部分に侵入したり広がったりする可能性を持つ、細胞の異常増殖を伴う一群の疾患です。がんは多くの場合、全身に転移する性質があります。世界では死因の第2位を占めています。がん遺伝子治療は、がん患者の遺伝子に治療用DNAを導入することで、がんの治療を行う技術です。技術の進歩に伴い、遺伝子治療市場はここ数年で変貌を遂げました。がん遺伝子治療は、がん患者の遺伝子に治療用DNAを導入することで、がんの治療を行う技術です。前臨床試験や臨床試験での成功率が高いことから、がん遺伝子治療は人気を博しています。がん遺伝子治療には、変異した遺伝子を健康な遺伝子に置き換える方法や、機能異常のある遺伝子を不活性化する方法など、さまざまな手法が用いられています。最近では、新しい遺伝子を体内に導入して、がん細胞と闘うという新しい手法も開発されています。
癌の有病率の上昇、従来の癌治療に対する癌遺伝子治療の利点、およびこの分野の進歩が市場成長の主な要因となっています。また、政府による支援の急増、がん治療における遺伝子治療の倫理的受容、バイオテクノロジー関連資金の増加が、がん遺伝子治療の研究開発活動を促進し、がん遺伝子治療市場の成長を後押ししています。また、がん遺伝子治療に関する認知度の向上も、世界のがん遺伝子治療市場の成長を促進する主な要因となっています。また、遺伝子治療研究に対する政府支援の増加、がん治療における遺伝子治療の倫理的受容、がんの有病率の上昇も、がん遺伝子治療市場の成長を後押ししています。しかし、治療や不要な免疫反応に関連する高コストが市場成長を抑制すると予想されます。
がん遺伝子治療市場は、治療法、エンドユーザー、地域に基づいて区分されます。治療法別では、遺伝子誘導免疫療法、腫瘍溶解性ウイルス療法、遺伝子導入療法に分類されます。エンドユーザー別では、病院、診断センター、研究機関に分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。
世界のがん遺伝子治療市場で事業を展開している主要企業には、Adaptimmune、GlaxoSmithKline、Bluebird bio, Inc.、Merck、Celgene、Shanghai Sunway Biotech、BioCancell、 Shenzhen SiBionoGeneTech、 SynerGene Therapeutics、OncoGenex Pharmaceuticalsが含まれます。
バリューチェーンの他の著名なプレーヤーには、Genelux Corporation、Cell Genesys、Advantagene、GenVec、BioCancell、Celgene、Epeius Biotechnologies、Introgen Therapeutics、Ziopharm Oncology、 Shenzhen SiBionoGeneTech、および Altor Bioscience が含まれています。

ページTOPに戻る

目次

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: CANCER GENE THERAPY MARKET, BY THERAPY
4.1 Overview
4.1.1 Market size and forecast
4.2 Gene Induced Immunotherapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oncolytic Virotherapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Gene Transfer
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: CANCER GENE THERAPY MARKET, BY END USER
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospitals
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Diagnostic centers
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Research Institutes
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: CANCER GENE THERAPY MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Therapy
6.2.3 North America Market size and forecast, by End User
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Therapy
6.2.4.1.2 Market size and forecast, by End User
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Therapy
6.2.4.2.2 Market size and forecast, by End User
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Therapy
6.2.4.3.2 Market size and forecast, by End User
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Therapy
6.3.3 Europe Market size and forecast, by End User
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Therapy
6.3.4.1.2 Market size and forecast, by End User
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Therapy
6.3.4.2.2 Market size and forecast, by End User
6.3.4.3 U.K.
6.3.4.3.1 Market size and forecast, by Therapy
6.3.4.3.2 Market size and forecast, by End User
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Therapy
6.3.4.4.2 Market size and forecast, by End User
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Therapy
6.3.4.5.2 Market size and forecast, by End User
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Therapy
6.3.4.6.2 Market size and forecast, by End User
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Therapy
6.4.3 Asia-Pacific Market size and forecast, by End User
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Market size and forecast, by Therapy
6.4.4.1.2 Market size and forecast, by End User
6.4.4.2 China
6.4.4.2.1 Market size and forecast, by Therapy
6.4.4.2.2 Market size and forecast, by End User
6.4.4.3 Australia
6.4.4.3.1 Market size and forecast, by Therapy
6.4.4.3.2 Market size and forecast, by End User
6.4.4.4 India
6.4.4.4.1 Market size and forecast, by Therapy
6.4.4.4.2 Market size and forecast, by End User
6.4.4.5 South Korea
6.4.4.5.1 Market size and forecast, by Therapy
6.4.4.5.2 Market size and forecast, by End User
6.4.4.6 Rest Of Asia Pacific
6.4.4.6.1 Market size and forecast, by Therapy
6.4.4.6.2 Market size and forecast, by End User
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Therapy
6.5.3 LAMEA Market size and forecast, by End User
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Therapy
6.5.4.1.2 Market size and forecast, by End User
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Therapy
6.5.4.2.2 Market size and forecast, by End User
6.5.4.3 South Africa
6.5.4.3.1 Market size and forecast, by Therapy
6.5.4.3.2 Market size and forecast, by End User
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Therapy
6.5.4.4.2 Market size and forecast, by End User
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Bristol Myers Squibb Co.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Novartis
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Amgen Inc.
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Glaxosmithkline PLC
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Kayropharma Therapeutics
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Gilead Sciences
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Adapta Immue
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Genulex Corporation
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 SynerGene Therapeutics
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 shanghai sunway biotech
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments


LIST OF TABLES
TABLE 1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 2. CANCER GENE THERAPY MARKET REVENUE, FOR GENE INDUCED IMMUNOTHERAPY, BY REGION , 2020-2030,($MILLION)
TABLE 3. CANCER GENE THERAPY MARKET GENE INDUCED IMMUNOTHERAPY BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. CANCER GENE THERAPY MARKET REVENUE, FOR ONCOLYTIC VIROTHERAPY, BY REGION , 2020-2030,($MILLION)
TABLE 5. CANCER GENE THERAPY MARKET ONCOLYTIC VIROTHERAPY BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. CANCER GENE THERAPY MARKET REVENUE, FOR GENE TRANSFER, BY REGION , 2020-2030,($MILLION)
TABLE 7. CANCER GENE THERAPY MARKET GENE TRANSFER BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. GLOBAL CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 9. CANCER GENE THERAPY MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION)
TABLE 10. CANCER GENE THERAPY MARKET HOSPITALS BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. CANCER GENE THERAPY MARKET REVENUE, FOR DIAGNOSTIC CENTERS, BY REGION , 2020-2030,($MILLION)
TABLE 12. CANCER GENE THERAPY MARKET DIAGNOSTIC CENTERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. CANCER GENE THERAPY MARKET REVENUE, FOR RESEARCH INSTITUTES, BY REGION , 2020-2030,($MILLION)
TABLE 14. CANCER GENE THERAPY MARKET RESEARCH INSTITUTES BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. CANCER GENE THERAPY MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 16. NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 17. NORTH AMERICA CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 18. NORTH AMERICA CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 19. U.S. CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 20. U.S. CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 21. CANADA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 22. CANADA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 23. MEXICO CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 24. MEXICO CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 25. EUROPE CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 26. EUROPE CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 27. EUROPE CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 28. GERMANY CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 29. GERMANY CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 30. FRANCE CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 31. FRANCE CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 32. U.K. CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 33. U.K. CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 34. ITALY CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 35. ITALY CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 36. SPAIN CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 37. SPAIN CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 38. REST OF EUROPE CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 39. REST OF EUROPE CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 40. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 41. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 42. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 43. JAPAN CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 44. JAPAN CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 45. CHINA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 46. CHINA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 47. AUSTRALIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 48. AUSTRALIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 49. INDIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 50. INDIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 51. SOUTH KOREA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 52. SOUTH KOREA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 53. REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 54. REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 55. LAMEA CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
TABLE 56. LAMEA CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 57. LAMEA CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 58. BRAZIL CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 59. BRAZIL CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 60. SAUDI ARABIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 61. SAUDI ARABIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 62. SOUTH AFRICA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 63. SOUTH AFRICA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 64. REST OF LAMEA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
TABLE 65. REST OF LAMEA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
TABLE 66.BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT
TABLE 67.BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS
TABLE 68.BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO
TABLE 69.BRISTOL MYERS SQUIBB CO.: NET SALES,
TABLE 70.BRISTOL MYERS SQUIBB CO.: KEY STRATERGIES
TABLE 71.NOVARTIS: COMPANY SNAPSHOT
TABLE 72.NOVARTIS: OPERATING SEGMENTS
TABLE 73.NOVARTIS: PRODUCT PORTFOLIO
TABLE 74.NOVARTIS: NET SALES,
TABLE 75.NOVARTIS: KEY STRATERGIES
TABLE 76.AMGEN INC.: COMPANY SNAPSHOT
TABLE 77.AMGEN INC.: OPERATING SEGMENTS
TABLE 78.AMGEN INC.: PRODUCT PORTFOLIO
TABLE 79.AMGEN INC.: NET SALES,
TABLE 80.AMGEN INC.: KEY STRATERGIES
TABLE 81.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 82.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 83.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 84.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 85.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 86.KAYROPHARMA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 87.KAYROPHARMA THERAPEUTICS: OPERATING SEGMENTS
TABLE 88.KAYROPHARMA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 89.KAYROPHARMA THERAPEUTICS: NET SALES,
TABLE 90.KAYROPHARMA THERAPEUTICS: KEY STRATERGIES
TABLE 91.GILEAD SCIENCES: COMPANY SNAPSHOT
TABLE 92.GILEAD SCIENCES: OPERATING SEGMENTS
TABLE 93.GILEAD SCIENCES: PRODUCT PORTFOLIO
TABLE 94.GILEAD SCIENCES: NET SALES,
TABLE 95.GILEAD SCIENCES: KEY STRATERGIES
TABLE 96.ADAPTA IMMUE: COMPANY SNAPSHOT
TABLE 97.ADAPTA IMMUE: OPERATING SEGMENTS
TABLE 98.ADAPTA IMMUE: PRODUCT PORTFOLIO
TABLE 99.ADAPTA IMMUE: NET SALES,
TABLE 100.ADAPTA IMMUE: KEY STRATERGIES
TABLE 101.GENULEX CORPORATION: COMPANY SNAPSHOT
TABLE 102.GENULEX CORPORATION: OPERATING SEGMENTS
TABLE 103.GENULEX CORPORATION: PRODUCT PORTFOLIO
TABLE 104.GENULEX CORPORATION: NET SALES,
TABLE 105.GENULEX CORPORATION: KEY STRATERGIES
TABLE 106.SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 107.SYNERGENE THERAPEUTICS: OPERATING SEGMENTS
TABLE 108.SYNERGENE THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 109.SYNERGENE THERAPEUTICS: NET SALES,
TABLE 110.SYNERGENE THERAPEUTICS: KEY STRATERGIES
TABLE 111.SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT
TABLE 112.SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS
TABLE 113.SHANGHAI SUNWAY BIOTECH: PRODUCT PORTFOLIO
TABLE 114.SHANGHAI SUNWAY BIOTECH: NET SALES,
TABLE 115.SHANGHAI SUNWAY BIOTECH: KEY STRATERGIES


LIST OF FIGURES
FIGURE 1.CANCER GENE THERAPY MARKET SEGMENTATION
FIGURE 2.CANCER GENE THERAPY MARKET,2020-2030
FIGURE 3.CANCER GENE THERAPY MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.CANCER GENE THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.CANCER GENE THERAPY MARKET,BY THERAPY,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF GENE INDUCED IMMUNOTHERAPY CANCER GENE THERAPY MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ONCOLYTIC VIROTHERAPY CANCER GENE THERAPY MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GENE TRANSFER CANCER GENE THERAPY MARKET,2020-2030(%)
FIGURE 15.CANCER GENE THERAPY MARKET,BY END USER,2020(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HOSPITALS CANCER GENE THERAPY MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS CANCER GENE THERAPY MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF RESEARCH INSTITUTES CANCER GENE THERAPY MARKET,2020-2030(%)
FIGURE 19.CANCER GENE THERAPY MARKET BY REGION,2020
FIGURE 20.U.S. CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 21.CANADA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 22.MEXICO CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 23.GERMANY CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 24.FRANCE CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 25.U.K. CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 26.ITALY CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 27.SPAIN CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 28.REST OF EUROPE CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 29.JAPAN CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 30.CHINA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 31.AUSTRALIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 32.INDIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 33.SOUTH KOREA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 34.REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 35.BRAZIL CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 36.SAUDI ARABIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 37.SOUTH AFRICA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 38.REST OF LAMEA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 43.COMPETITIVE DASHBOARD
FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 45.BRISTOL MYERS SQUIBB CO..: NET SALES ,($MILLION)
FIGURE 46.NOVARTIS.: NET SALES ,($MILLION)
FIGURE 47.AMGEN INC..: NET SALES ,($MILLION)
FIGURE 48.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
FIGURE 49.KAYROPHARMA THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 50.GILEAD SCIENCES.: NET SALES ,($MILLION)
FIGURE 51.ADAPTA IMMUE.: NET SALES ,($MILLION)
FIGURE 52.GENULEX CORPORATION.: NET SALES ,($MILLION)
FIGURE 53.SYNERGENE THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 54.SHANGHAI SUNWAY BIOTECH.: NET SALES ,($MILLION)